{
    "info": {
        "nct_id": "NCT02159248",
        "official_title": "09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy",
        "inclusion_criteria": "1. Patients must have histologically or cytologically confirmed:\n\n   1. Locally advanced (potentially resectable) pancreatic adenocarcinoma requiring neoadjuvant radiation or\n   2. Locally advanced (nonresectable) or metastatic pancreatic adenocarcinoma requiring definitive or palliative radiation therapy\n2. Patients may have either measurable or non-measurable disease (according to RECIST criteria, Version 1.1).\n3. Age ≥ 18 years\n4. ECOG performance status of 0 or 1.\n5. A life expectancy of at least 12 weeks.\n6. No other concurrent radiotherapy, chemotherapy or immunotherapy.\n7. A minimum of 4 weeks must have elapsed since completion of any prior chemotherapy or immunotherapy.\n8. Patient must have:\n\n   1. Absolute neutrophil count (ANC) ≥1,000/mm3\n   2. Platelets ≥100,000/mm3\n   3. Hemoglobin ≥10 g/dL [Transfusion to meet the hemoglobin requirement is acceptable]\n   4. Serum creatinine ≤ 1.5 X ULN\n   5. Total bilirubin ≤ 1.5 X ULN\n   6. Aspartate aminotransferase (AST) ≤ 2.5 X ULN\n   7. Alanine aminotransferase (ALT) ≤ 2.5 X ULN\n   8. Alkaline phosphatase ≤ 2.5 X ULN\n   9. PT/INR ≤ 1.5 X ULN\n   10. aPTT ≤ 1.5 X ULN\n   11. Urine Protein ≤ Grade 1\n9. For patients on warfarin: Must have maintained a stable INR on a stable dose of warfarin for at least 4 weeks prior to start of treatment.\n\nPrimary\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patients who have received prior radiation for their current malignancy at the location of interest.\n2. Patients who have not recovered (to Grade 1 or less) from adverse events, other than alopecia and neuropathy, caused by previously administered chemotherapeutic agents, at the discretion of the PI/treating physician.\n3. Tolfenamic acid use concurrent with, or within 8 weeks prior to the diagnosis of pancreatic cancer.\n4. Current use of any non-steroidal anti-inflammatory agents (NSAIDs), including aspirin, (other than tolfenamic acid) within 4 weeks prior to the start of active treatment.\n5. Previous history of hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to ibuprofen, aspirin or other NSAIDs.\n6. History of recurrent peptic ulcer/hemorrhage (two or more distinct episodes).\n7. History of gastrointestinal bleeding or perforation related to previous use of NSAIDS.\n8. New York Heart Association Functional Classification of 3 or 4.\n9. Known autoimmune disease that could preclude the use of radiation, at the discretion of the treating physician.\n10. History or evidence of CNS disease (e.g., any brain metastases, primary brain tumor, seizures not controlled with standard medical therapy, or history of stroke).\n11. Known HIV positive.\n12. Active systemic infection requiring parenteral antibiotic therapy.\n13. Receiving systemic steroid therapy. (Inhaled steroid therapy is allowable.)\n14. History of other malignancies within the last 5 years with the exception of non- melanoma skin cancer or cervical cancer in situ that has been successfully treated.",
        "miscellaneous_criteria": "Primary"
    },
    "inclusion_lines": [
        {
            "line": "1. Patients must have histologically or cytologically confirmed:",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "cancer diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Locally advanced (potentially resectable) pancreatic adenocarcinoma requiring neoadjuvant radiation or",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced (potentially resectable) pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "locally advanced"
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "potentially resectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring neoadjuvant radiation",
                    "criterion": "neoadjuvant radiation",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Locally advanced (nonresectable) or metastatic pancreatic adenocarcinoma requiring definitive or palliative radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced (nonresectable) or metastatic pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced (nonresectable)",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring definitive or palliative radiation therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": [
                                "definitive",
                                "palliative"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients may have either measurable or non-measurable disease (according to RECIST criteria, Version 1.1).",
            "criterions": [
                {
                    "exact_snippets": "measurable or non-measurable disease (according to RECIST criteria, Version 1.1)",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. ECOG performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. A life expectancy of at least 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of at least 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. No other concurrent radiotherapy, chemotherapy or immunotherapy.",
            "criterions": [
                {
                    "exact_snippets": "No other concurrent radiotherapy",
                    "criterion": "concurrent radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No other concurrent ... chemotherapy",
                    "criterion": "concurrent chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No other concurrent ... immunotherapy",
                    "criterion": "concurrent immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. A minimum of 4 weeks must have elapsed since completion of any prior chemotherapy or immunotherapy.",
            "criterions": [
                {
                    "exact_snippets": "A minimum of 4 weeks must have elapsed since completion of any prior chemotherapy",
                    "criterion": "elapsed time since prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time elapsed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "A minimum of 4 weeks must have elapsed since completion of any prior ... immunotherapy",
                    "criterion": "elapsed time since prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time elapsed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count (ANC) ≥1,000/mm3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥1,000/mm3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelets ≥100,000/mm3",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥100,000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin ≥10 g/dL [Transfusion to meet the hemoglobin requirement is acceptable]",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥10 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serum creatinine ≤ 1.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 1.5 X ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Total bilirubin ≤ 1.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 X ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Aspartate aminotransferase (AST) ≤ 2.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ≤ 2.5 X ULN",
                    "criterion": "Aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Alanine aminotransferase (ALT) ≤ 2.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ≤ 2.5 X ULN",
                    "criterion": "Alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Alkaline phosphatase ≤ 2.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase ≤ 2.5 X ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. PT/INR ≤ 1.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "PT/INR ≤ 1.5 X ULN",
                    "criterion": "PT/INR",
                    "requirements": [
                        {
                            "requirement_type": "comparison",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. aPTT ≤ 1.5 X ULN",
            "criterions": [
                {
                    "exact_snippets": "aPTT ≤ 1.5 X ULN",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Urine Protein ≤ Grade 1",
            "criterions": [
                {
                    "exact_snippets": "Urine Protein ≤ Grade 1",
                    "criterion": "urine protein",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. For patients on warfarin: Must have maintained a stable INR on a stable dose of warfarin for at least 4 weeks prior to start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "patients on warfarin",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable INR",
                    "criterion": "INR stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable dose of warfarin",
                    "criterion": "warfarin dose stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 4 weeks prior to start of treatment",
                    "criterion": "duration of stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Patients who have received prior radiation for their current malignancy at the location of interest.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior radiation for their current malignancy at the location of interest.",
                    "criterion": "prior radiation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients who have not recovered (to Grade 1 or less) from adverse events, other than alopecia and neuropathy, caused by previously administered chemotherapeutic agents, at the discretion of the PI/treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have not recovered (to Grade 1 or less) from adverse events ... caused by previously administered chemotherapeutic agents",
                    "criterion": "recovery from adverse events",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other than alopecia and neuropathy",
                    "criterion": "adverse events",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "alopecia",
                                "neuropathy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Tolfenamic acid use concurrent with, or within 8 weeks prior to the diagnosis of pancreatic cancer.",
            "criterions": [
                {
                    "exact_snippets": "Tolfenamic acid use concurrent with, or within 8 weeks prior to the diagnosis of pancreatic cancer.",
                    "criterion": "Tolfenamic acid use",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "concurrent with, or within 8 weeks prior to the diagnosis of pancreatic cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Current use of any non-steroidal anti-inflammatory agents (NSAIDs), including aspirin, (other than tolfenamic acid) within 4 weeks prior to the start of active treatment.",
            "criterions": [
                {
                    "exact_snippets": "Current use of any non-steroidal anti-inflammatory agents (NSAIDs), including aspirin, (other than tolfenamic acid) within 4 weeks prior to the start of active treatment.",
                    "criterion": "use of non-steroidal anti-inflammatory agents (NSAIDs)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Current use of ... aspirin ... within 4 weeks prior to the start of active treatment.",
                    "criterion": "use of aspirin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Current use of ... tolfenamic acid ... within 4 weeks prior to the start of active treatment.",
                    "criterion": "use of tolfenamic acid",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Previous history of hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to ibuprofen, aspirin or other NSAIDs.",
            "criterions": [
                {
                    "exact_snippets": "Previous history of hypersensitivity reactions ... in response to ibuprofen, aspirin or other NSAIDs.",
                    "criterion": "hypersensitivity reactions",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria)",
                    "criterion": "asthma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria)",
                    "criterion": "rhinitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria)",
                    "criterion": "angioedema",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria)",
                    "criterion": "urticaria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in response to ibuprofen, aspirin or other NSAIDs",
                    "criterion": "ibuprofen",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "hypersensitivity"
                        }
                    ]
                },
                {
                    "exact_snippets": "in response to ibuprofen, aspirin or other NSAIDs",
                    "criterion": "aspirin",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "hypersensitivity"
                        }
                    ]
                },
                {
                    "exact_snippets": "in response to ibuprofen, aspirin or other NSAIDs",
                    "criterion": "other NSAIDs",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "hypersensitivity"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. History of recurrent peptic ulcer/hemorrhage (two or more distinct episodes).",
            "criterions": [
                {
                    "exact_snippets": "History of recurrent peptic ulcer",
                    "criterion": "recurrent peptic ulcer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "episodes"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of recurrent ... hemorrhage",
                    "criterion": "recurrent hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "episodes"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of gastrointestinal bleeding or perforation related to previous use of NSAIDS.",
            "criterions": [
                {
                    "exact_snippets": "History of gastrointestinal bleeding",
                    "criterion": "gastrointestinal bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "perforation related to previous use of NSAIDS",
                    "criterion": "perforation related to NSAIDS",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. New York Heart Association Functional Classification of 3 or 4.",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Functional Classification of 3 or 4",
                    "criterion": "New York Heart Association Functional Classification",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Known autoimmune disease that could preclude the use of radiation, at the discretion of the treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Known autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "could preclude the use of radiation",
                    "criterion": "use of radiation",
                    "requirements": [
                        {
                            "requirement_type": "preclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. History or evidence of CNS disease (e.g., any brain metastases, primary brain tumor, seizures not controlled with standard medical therapy, or history of stroke).",
            "criterions": [
                {
                    "exact_snippets": "History or evidence of CNS disease ... brain metastases",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or evidence of CNS disease ... primary brain tumor",
                    "criterion": "primary brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or evidence of CNS disease ... seizures not controlled with standard medical therapy",
                    "criterion": "seizures",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "not controlled with standard medical therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "History or evidence of CNS disease ... history of stroke",
                    "criterion": "history of stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Known HIV positive.",
            "criterions": [
                {
                    "exact_snippets": "Known HIV positive.",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Active systemic infection requiring parenteral antibiotic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active systemic infection",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring parenteral antibiotic therapy",
                    "criterion": "antibiotic therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration route",
                            "expected_value": "parenteral"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Receiving systemic steroid therapy. (Inhaled steroid therapy is allowable.)",
            "criterions": [
                {
                    "exact_snippets": "Receiving systemic steroid therapy.",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Inhaled steroid therapy is allowable.",
                    "criterion": "inhaled steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of other malignancies within the last 5 years with the exception of non- melanoma skin cancer or cervical cancer in situ that has been successfully treated.",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancies within the last 5 years",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of non- melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of ... cervical cancer in situ that has been successfully treated",
                    "criterion": "cervical cancer in situ",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "successfully treated"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "8. Patient must have:",
            "criterions": []
        },
        {
            "line": "Primary",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": [
        {
            "line": "Primary",
            "criterions": []
        }
    ]
}